Fulvestrant IM Injection

Fulvestrant IM Injection 250 mg/5 ml Introduction

Fulvestrant IM Injection 250 mg/5 ml is a type of hormone therapy used to treat certain types of breast cancer in postmenopausal women. It belongs to a group of medications known as aromatase inhibitors. Fulvestrant IM Injection 250 mg/5 ml works by blocking the effects of the naturally occurring hormone estrogen in the body. This helps to slow down the growth of certain types of breast cancer tumors that rely on estrogen to grow.

Uses for

Fulvestrant IM Injection 250 mg/5 ml is used to treat postmenopausal women with hormone-receptor positive or estrogen-receptor positive (ER-positive) metastatic breast cancer that has progressed after treatment with certain other medications. ER-positive means that the cancer cells have receptors which attach to the hormone estrogen. Fulvestrant IM Injection 250 mg/5 ml helps slow down the growth of tumor cells that have these receptors.

Brand Name	Fulvestrant
Type	IM Injection
Weight	250 mg/5 ml
Generic	Fulvestrant
Manufacturer	ZAS Corporation
Available in	English বাংলা

Mechanism of Action

Fulvestrant IM Injection 250 mg/5 ml works by blocking the effects of estrogen on cancer cells. Estrogen is a hormone that can stimulate the growth of certain types of breast cancer cells that have hormone receptors. By blocking the effects of estrogen, Fulvestrant IM Injection 250 mg/5 ml can slow down the growth of these types of tumors.

How Long Does It Take To Work?

Fulvestrant IM Injection 250 mg/5 ml can take some time to start working. Results have typically been seen within 6 weeks of starting treatment. It is important to note that Fulvestrant IM Injection 250 mg/5 ml should be used in combination with other treatments and should not be used as a sole treatment.

Absorption

Fulvestrant IM Injection 250 mg/5 ml absorbed quickly and completely after intramuscular injection. The maximum concentration is reached in around 1-2 hours. It is rapidly eliminated from the body with a half-life of around 6 hours.

Route of Elimination

Fulvestrant IM Injection 250 mg/5 ml is metabolized by the liver and eliminated through urine and feces. It is mostly eliminated by the kidneys, with a small amount excreted in the bile.

Dosage

Fulvestrant 500 mg should be administered intramuscularly into the buttocks (gluteal area) slowly (1-2 minutes per injection) as two 5 mL injections, one in each buttock, on Days 1, 15, 29, and once monthly thereafter.

A dose of 250 mg is recommended in patients with moderate hepatic impairment to be administered intramuscularly into the buttock (gluteal area) slowly (1-2 minutes) as one 5 mL injection on Days 1, 15, 29, and once monthly thereafter.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Fulvestrant IM Injection 250 mg/5 ml is injected into the upper arm, thigh, or buttocks once a month. The recommended dose is 500 mg as an intramuscular injection once a month for 1 year. The dose can be increased to 750 mg once a month for the second year if the initial treatment results were successful.

Administration

Fulvestrant IM Injection 250 mg/5 ml should only be administered by a health care professional. It should be injected into the upper arm, thigh, or buttocks. All injections should be done aseptically and with the correct needles and syringes.

Side Effects

Common side effects of Fulvestrant IM Injection 250 mg/5 ml include fatigue, nausea, and vomiting, headache, skin rash or itching, abdominal or pelvic pain, hot flashes, and joint pain. Serious side effects include bone pain, bone fractures, and decreased bone mineral density. It is important to speak to a health care provider about any side effects that are experienced.

Toxicity

In general, Fulvestrant IM Injection 250 mg/5 ml is well tolerated. However, it is important to be aware of the potential for toxicity of the medication. This includes hypersensitivity, pulmonary embolism, and deep vein thrombosis. It is important to speak to a doctor about any potential toxicity before beginning treatment.

Precautions

Fulvestrant IM Injection 250 mg/5 ml is not recommended for use in patients with liver or renal impairment. It should not be used in patients with a known hypersensitivity to the medication or any of its ingredients. It is important to tell your doctor about all medications you are taking before beginning Fulvestrant IM Injection 250 mg/5 ml.

Interaction

Fulvestrant IM Injection 250 mg/5 ml may interact with other medications and supplements. It is important to tell your doctor about any medications or supplements you are taking before beginning Fulvestrant IM Injection 250 mg/5 ml. This includes prescription medications, over the counter medications, vitamins, and herbal remedies.

Disease Interaction

Fulvestrant IM Injection 250 mg/5 ml should not be used in patients with a preexisting liver or renal disease. It is important to tell your doctor about any other illnesses you have before beginning Fulvestrant IM Injection 250 mg/5 ml.

Drug Interaction

Fulvestrant IM Injection 250 mg/5 ml may interact with certain medications. It is important to tell your doctor about any medications or supplements you are taking before beginning Fulvestrant IM Injection 250 mg/5 ml. This includes prescription medications, over the counter medications, vitamins, and herbal remedies.

Food Interactions

Fulvestrant IM Injection 250 mg/5 ml does not interact with food, however, it is important to drink plenty of water while taking Fulvestrant IM Injection 250 mg/5 ml to prevent dehydration.

Pregnancy Use

Fulvestrant IM Injection 250 mg/5 ml should not be used during pregnancy. If you are pregnant or planning to become pregnant, you should talk to your doctor about the risks and benefits of taking Fulvestrant IM Injection 250 mg/5 ml.

Lactation Use

Fulvestrant IM Injection 250 mg/5 ml should not be used while breastfeeding. If you are breastfeeding or planning to breastfeed, you should talk to your doctor about the risks and benefits of taking Fulvestrant IM Injection 250 mg/5 ml.

Acute Overdose

If an overdose of Fulvestrant IM Injection 250 mg/5 ml occurs, seek medical attention immediately. Symptoms of an overdose may include nausea, vomiting, abdominal pain, and dizziness.

Contraindication

Fulvestrant IM Injection 250 mg/5 ml should not be used in patients with a known hypersensitivity to the medication or any of its ingredients. It is also contraindicated in patients with liver or renal impairment. It should not be used in pregnant or breastfeeding women.

Uses Direction

Fulvestrant IM Injection 250 mg/5 ml should be injected into the upper arm, thigh, or buttocks once a month. Follow your doctor's instructions carefully for the correct dosage and method of administration.

Storage Condition

Fulvestrant IM Injection 250 mg/5 ml should be stored in a refrigerator at 2-25°C. Keep it in the original package and away from direct light.

Volume of Distribution

Fulvestrant IM Injection 250 mg/5 ml has an average volume of distribution of about 6-7 L/kg. This means that the drug is found in all areas of the body, including the liver, kidneys, muscles, and fat.

Half Life

Fulvestrant IM Injection 250 mg/5 ml has a half-life of approximately 6-7 hours. This means that after 6-7 hours the concentration of the drug in the blood will be halved.

Clearance

Fulvestrant IM Injection 250 mg/5 ml is cleared from the body by the liver, with approximately 80% of the drug being eliminated this way. The remaining 20% is mainly eliminated by the kidneys.

See in details version Fulvestrant IM Injection 250 mg/5 ml also Fulvestrant IM Injection 250 mg/5 ml in bangla